226 related articles for article (PubMed ID: 24112243)
1. In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex.
Lavollay M; Dubée V; Heym B; Herrmann JL; Gaillard JL; Gutmann L; Arthur M; Mainardi JL
Clin Microbiol Infect; 2014 May; 20(5):O297-300. PubMed ID: 24112243
[TBL] [Abstract][Full Text] [Related]
2. [Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing].
Gui J; Wang F; Hong CY; Li JL; Liang J
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Aug; 36(8):567-71. PubMed ID: 24252731
[TBL] [Abstract][Full Text] [Related]
3. Species identification of Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii using rpoB and hsp65, and susceptibility testing to eight antibiotics.
Nie W; Duan H; Huang H; Lu Y; Bi D; Chu N
Int J Infect Dis; 2014 Aug; 25():170-4. PubMed ID: 24932856
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex.
Singh S; Bouzinbi N; Chaturvedi V; Godreuil S; Kremer L
Clin Microbiol Infect; 2014 Dec; 20(12):O1124-7. PubMed ID: 25185732
[TBL] [Abstract][Full Text] [Related]
5. Effect of β-lactamase production and β-lactam instability on MIC testing results for Mycobacterium abscessus.
Rominski A; Schulthess B; Müller DM; Keller PM; Sander P
J Antimicrob Chemother; 2017 Nov; 72(11):3070-3078. PubMed ID: 28961987
[TBL] [Abstract][Full Text] [Related]
6. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.
Woods GL; Bergmann JS; Witebsky FG; Fahle GA; Wanger A; Boulet B; Plaunt M; Brown BA; Wallace RJ
J Clin Microbiol; 1999 Jun; 37(6):1676-82. PubMed ID: 10325306
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Interactions of Indole-2-Carboxamides and β-Lactam Antibiotics against Mycobacterium abscessus.
Raynaud C; Daher W; Roquet-Banères F; Johansen MD; Stec J; Onajole OK; Ordway D; Kozikowski AP; Kremer L
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041716
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
[TBL] [Abstract][Full Text] [Related]
9. Bactericidal and intracellular activity of β-lactams against Mycobacterium abscessus.
Lefebvre AL; Dubée V; Cortes M; Dorchêne D; Arthur M; Mainardi JL
J Antimicrob Chemother; 2016 Jun; 71(6):1556-63. PubMed ID: 26929268
[TBL] [Abstract][Full Text] [Related]
10. In vitro efficacy of imipenem in combination with six antimicrobial agents against Mycobacterium abscessus.
Miyasaka T; Kunishima H; Komatsu M; Tamai K; Mitsutake K; Kanemitsu K; Ohisa Y; Yanagisawa H; Kaku M
Int J Antimicrob Agents; 2007 Sep; 30(3):255-8. PubMed ID: 17616451
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest.
Brown-Elliott BA; Killingley J; Vasireddy S; Bridge L; Wallace RJ
J Clin Microbiol; 2016 Jun; 54(6):1586-1592. PubMed ID: 27053677
[TBL] [Abstract][Full Text] [Related]
12.
Brown-Elliott BA; Wallace RJ
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509936
[TBL] [Abstract][Full Text] [Related]
13. Characterization of rough and smooth morphotypes of Mycobacterium abscessus isolates from clinical specimens.
Rüger K; Hampel A; Billig S; Rücker N; Suerbaum S; Bange FC
J Clin Microbiol; 2014 Jan; 52(1):244-50. PubMed ID: 24197890
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing.
Huang YC; Liu MF; Shen GH; Lin CF; Kao CC; Liu PY; Shi ZY
J Microbiol Immunol Infect; 2010 Oct; 43(5):401-6. PubMed ID: 21075707
[TBL] [Abstract][Full Text] [Related]
15. Antimycobacterial activity of nonantibiotics associated with the polypharmacy of cystic fibrosis (CF) against mycobacterium abscessus.
Kirkwood ZI; Millar BC; Downey DG; Moore JE
Int J Mycobacteriol; 2018; 7(4):358-360. PubMed ID: 30531035
[TBL] [Abstract][Full Text] [Related]
16. Bacteraemia caused by Mycobacterium abscessus subsp. abscessus and M. abscessus subsp. bolletii: clinical features and susceptibilities of the isolates.
Lee MR; Ko JC; Liang SK; Lee SW; Yen DH; Hsueh PR
Int J Antimicrob Agents; 2014 May; 43(5):438-41. PubMed ID: 24718088
[TBL] [Abstract][Full Text] [Related]
17. The drug susceptibility profile and inducible resistance to macrolides of Mycobacterium abscessus and Mycobacterium massiliense in Korea.
Kim SY; Kim CK; Bae IK; Jeong SH; Yim JJ; Jung JY; Park MS; Kim YS; Kim SK; Chang J; Kang YA
Diagn Microbiol Infect Dis; 2015 Feb; 81(2):107-11. PubMed ID: 25467784
[TBL] [Abstract][Full Text] [Related]
18. Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies.
Mougari F; Bouziane F; Crockett F; Nessar R; Chau F; Veziris N; Sapriel G; Raskine L; Cambau E
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799212
[TBL] [Abstract][Full Text] [Related]
19. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan.
Huang CW; Chen JH; Hu ST; Huang WC; Lee YC; Huang CC; Shen GH
Int J Antimicrob Agents; 2013 Mar; 41(3):218-23. PubMed ID: 23312605
[TBL] [Abstract][Full Text] [Related]
20. [The analysis of species identification and susceptibility testing of Mycobacterium abscessus].
Nie W; Duan H; Huang H; Lu Y; Chu N
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jul; 37(7):517-21. PubMed ID: 25262693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
